The UK Health Security Agency (UKHSA) recently announced the launch of the United Kingdom’s first national study measuring levels of per- and polyfluoroalkyl substances (PFAS) in the population. Using blood and urine samples collected through the Health Survey for England, the study will establish baseline exposure data for PFAS and other environmental contaminants, with initial results expected in 2027.
The UK’s First National PFAS Biomonitoring Effort
According to UKHSA, the study will analyze blood and urine samples collected through the Health Survey for England, a long-running survey that gathers health information from thousands of individuals across the country. In addition to PFAS, researchers will measure other environmental contaminants, including lead, arsenic, bisphenols, phthalates, and flame retardants.
The study is intended to establish baseline exposure levels across the UK population and improve understanding of environmental exposures at a national scale. UKHSA has emphasized that questions remain regarding the relationship between exposure levels and long-term health outcomes, making additional population-based data valuable for future research.
At the same time, the agency has stated that current evidence suggests the health impacts associated with PFAS exposure are likely to be limited for most individuals. It does not recommend routine PFAS blood testing because there is no established clinical intervention tied solely to elevated PFAS levels.
Building a Population-Level Exposure Baseline
What distinguishes the UK initiative from many earlier PFAS studies is its focus on establishing a national baseline of exposure.
According to UKHSA, PFAS exposure is widespread due to decades of use in consumer products, industrial applications, and firefighting foams. Although low levels of certain PFAS compounds can be detected in much of the population, questions remain regarding how exposure varies across groups and how those data should be interpreted for public health purposes.
Large-scale biomonitoring studies help address those questions by identifying exposure patterns across broad populations and supporting future epidemiological research. By leveraging the Health Survey for England rather than creating an entirely new sampling program, UKHSA may be able to build a dataset that supports future evaluations of population-level PFAS exposure.
How the Study Compares to Earlier PFAS Biomonitoring Efforts
The UK initiative also reflects the broader role that biomonitoring has played in PFAS research internationally.
In the United States, some of the most prominent PFAS-related biomonitoring efforts arose from investigations into localized contamination. One example is the C8 Health Project, which examined PFOA exposure among residents living near chemical manufacturing facilities. The study enrolled more than 69,000 residents from communities in West Virginia and Ohio between 2005 and 2006. Unlike the UK effort, it was designed to evaluate exposure in communities affected by a known contamination source.
The UK’s initiative differs in an important respect. Rather than focusing on a community affected by a known contamination source, the study is designed to measure PFAS exposure across the general public. As a result, its primary value may be less about investigating a specific contamination event and more about characterizing PFAS exposure across the broader population.
Looking Ahead
The first results from the study are expected next year and will provide an initial snapshot of PFAS exposure within the UK population.
The resulting data may help researchers better understand how PFAS exposure varies across different demographic groups and provide important context for future biomonitoring efforts.
Ultimately, the study’s importance lies in its effort to move the conversation beyond the mere detection of PFAS and toward a clearer understanding of population-wide exposure patterns. As additional data become available, the study may help provide the scientific foundation needed to evaluate potential health risks using observed population-level trends rather than assumptions about exposure alone.
MG+M Law Clerk Iloe Vorbe is a contributing author of this article.
